<DOC>
	<DOCNO>NCT01937832</DOCNO>
	<brief_summary>The purpose study evaluate safety Efficacy Faropenem community-acquired pneumonia ( CAP ) subject</brief_summary>
	<brief_title>A Phase III Study Faropenem Treatment Adult Community-acquired Bacterial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>1 . Patients age between18~73 year , either male female 2 . Patients require hospitalization emergency room observation , need receive intravenous antibiotic treatment 3 . Women childbearing age negative pregnancy test time enrollment agree take effective contraceptive measure delivery 7 ~14 day stop . ( example : oral contraception , injectable contraception , implant contraception , spermicides condom , IUDs ) . 4 . Comply follow clinical , radiological microbiological criterion CommunityAcquired Pneumonia ( CAP ) 5 . Patients use ineffective systemic antimicrobial drug enrollment effective antimicrobial drug within 72h enrollment , use &lt; 24h 6 . Informed consent grant 1 . Patients atypical pneumonia infect Mycoplasma pneumoniae , Chlamydia pneumoniae , Legionella pneumophila bacteria ; 2 . Patients infected pathogen MRSA , Pseudomonas aeruginosa Acinetobacter baumannii ; 3 . Viral pneumonia ; 4 . Aspiration pneumonia ; 5 . Hospitalacquired pneumonia , include ventilatorassociated pneumonia ; 6 . Patients Severe pneumonia meet one primary criterion three secondary criterion ( See Appendix ) ; 7 . Patients rapid progressive endstage disease , survive end study period antibiotic treatment ; 8 . Patients bronchial obstruction history obstructive pneumonia ( include chronic obstructive pulmonary disease ) ; 9 . Suffering follow disease : active tuberculosis , bronchiectasis , lung abscess , lung cancer , noninfectious interstitial lung disease , pulmonary edema , atelectasis , pulmonary embolism , pulmonary eosinophil infiltration disease pulmonary vasculitis ; 10 . Infections acquire hospital , nurse home longterm care facility , patient hospitalize within 14 day prior enrollment ; 11 . Allergic penem carbapenem antibiotic ; 12 . Pregnancy lactation woman ; 13 . Patients uncontrolled psychiatric history risk suicide two year prior enrollment ; 14 . A history epilepsy central nervous system disorder patient ; 15 . Patients Renal dysfunction , screen serum creatinine value upper limit normal 10 % ; 16 . The Screening alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 3 time upper limit reference value , total bilirubin beyond upper limit normal range 10 % ; 17 . Serious disease affect immune system , : human immunodeficiency virus ( HIV ) infection history , CD4 + Tlymphocyte count &lt; 200/200/mm3 , Neutrophilic granulocytopenia ( neutrophil count &lt; 1500/mm3 ) , hematologic malignancy solid organ splenectomy , etc ; 18 . Patients take steroid medication , least 20mg daily dose prednisone ( equivalent dos glucocorticoid ) ; 19 . Patients accept chemotherapy drug therapy anticancer therapy , plan accept treatment trial six month prior enrollment ; 20 . Alcohol illicit drug abuse history ; 21 . Patients accept experimental drug within 3 month prior enrollment ; 22. 500ml blood donation within 3 month prior enrollment ; 23 . Patients participate clinical trial ever ; 24 . Combined use antibacterial drug patient ; 25 . Patients diagnosed potential increase risk , may interference clinical trial ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>